Melissa Pulitzer
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Melissa Pulitzer has a total of 299 co-authors. Here are the top co-authors by number of shared publications:
- Klaus Johannes Busam
Department of Pathology Memorial Sloan Kettering Cancer Center New York New York USA
13 shared publications - Alana J. Eagan
Memorial Sloan Kettering Cancer Center 2 Department of Epidemiology and Biostatistics New York, New York
11 shared publications - Christopher A. Barker
Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA
11 shared publications - Daniel William Scholfield
Head and Neck Service, Department of Surgery Memorial Sloan Kettering Cancer Center New York New York USA
11 shared publications - Emma Ann Finnegan
Head and Neck Service, Department of Surgery Memorial Sloan Kettering Cancer Center New York New York USA
11 shared publications - Fergal G. Kavanagh
Department of Surgery Memorial Sloan Kettering Cancer Center New York New York USA
11 shared publications
Latest Publications
- Open Access
- 1 September 2026
- Published by American Association for Cancer Research (AACR)
Data from Nonoperative Management of Locally Advanced Resectable Cutaneous Squamous Cell Cancer of the Head and Neck with PD-1 Blockade
Purpose:Neoadjuvant PD-1 blockade has shown marked efficacy before surgery in patients with head and neck cutaneous squamous cell cancinoma (CSCC). However, the potential for PD-1 blockade as a definitive, nonoperative therapy remains uncertain. Experimental Design:We conducted a single-institution retrospective study (2018 to 2023) of patients with locally advanced resectable stage III/IV CSCC treated with cemiplimab. Patients received neoadjuvant cemiplimab followed by surgery or cemiplimab monotherapy without surgery. The primary endpoint was the objective radiologic response rate (assessed using immune Response Evaluation Criteria in Solid Tumors) and clinical response rate; the secondary endpoints included disease-specific survival (DSS), progression-free probability (PFP), histopathologic response, and exploratory genomic biomarkers. Results:Fifty-one patients received cemiplimab monotherapy alone (median age: 78.8 years), and 21 received neoadjuvant cemiplimab followed by surgery (median age: 73 years). The 2-year DSS and PFP for cemiplimab monotherapy were 90% [95% confidence interval (CI), 80%–100%] and 82% (95% CI, 72%–94%), respectively. The 2-year DSS and PFP for neoadjuvant cemiplimab with surgery were 95% (95% CI, 86%–100%) and 78% (95% CI, 62%–100%), respectively. Tumor-infiltrating lymphocytes (TIL) were higher in patients with complete response (CR) or partial response (PR) than in patients with progressive disease (PD) or stable disease (P = 0.005, q = 0.026), with absent TILs more frequent in nonresponders. Tumor mutational burden was higher in CR (55.7) and PR (14.9) than in PD (4.9; P = 0.02, q = 0.04). Conclusions:In this retrospective, nonrandomized cohort, definitive-intent cemiplimab monotherapy was associated with durable disease control in selected patients with locally advanced resectable head and neck CSCC. This study provides a promising real-world organ preservation experience for patients with advanced head and neck CSCC treated with cemiplimab monotherapy that does not compromise oncologic outcomes.
- 1 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessData from Nonoperative Management of Locally Advanced Resectable Cutaneous Squamous Cell Cancer of the Head and Neck with PD-1 Blockade
Purpose:Neoadjuvant PD-1 blockade has shown marked efficacy before surgery in patients with head and neck cutaneous squamous cell cancinoma (CSCC). However, the potential for PD-1 blockade as a definitive, nonoperative therapy remains uncertain. Experimental Design:We conducted a single-institution retrospective study (2018 to 2023) of patients with locally advanced resectable stage III/IV CSCC treated with cemiplimab. Patients received neoadjuvant cemiplimab followed by surgery or cemiplimab monotherapy without surgery. The primary endpoint was the objective radiologic response rate (assessed using immune Response Evaluation Criteria in Solid Tumors) and clinical response rate; the secondary endpoints included disease-specific survival (DSS), progression-free probability (PFP), histopathologic response, and exploratory genomic biomarkers. Results:Fifty-one patients received cemiplimab monotherapy alone (median age: 78.8 years), and 21 received neoadjuvant cemiplimab followed by surgery (median age: 73 years). The 2-year DSS and PFP for cemiplimab monotherapy were 90% [95% confidence interval (CI), 80%–100%] and 82% (95% CI, 72%–94%), respectively. The 2-year DSS and PFP for neoadjuvant cemiplimab with surgery were 95% (95% CI, 86%–100%) and 78% (95% CI, 62%–100%), respectively. Tumor-infiltrating lymphocytes (TIL) were higher in patients with complete response (CR) or partial response (PR) than in patients with progressive disease (PD) or stable disease (P = 0.005, q = 0.026), with absent TILs more frequent in nonresponders. Tumor mutational burden was higher in CR (55.7) and PR (14.9) than in PD (4.9; P = 0.02, q = 0.04). Conclusions:In this retrospective, nonrandomized cohort, definitive-intent cemiplimab monotherapy was associated with durable disease control in selected patients with locally advanced resectable head and neck CSCC. This study provides a promising real-world organ preservation experience for patients with advanced head and neck CSCC treated with cemiplimab monotherapy that does not compromise oncologic outcomes.
- Open Access
- 1 September 2026
- Published by American Association for Cancer Research (AACR)
Supplemental Figure 1 from Nonoperative Management of Locally Advanced Resectable Cutaneous Squamous Cell Cancer of the Head and Neck with PD-1 Blockade
Supplemental Figure 1 from Nonoperative Management of Locally Advanced Resectable Cutaneous Squamous Cell Cancer of the Head and Neck with PD-1 Blockade
- 1 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure 1 from Nonoperative Management of Locally Advanced Resectable Cutaneous Squamous Cell Cancer of the Head and Neck with PD-1 Blockade
Supplemental Figure 1 from Nonoperative Management of Locally Advanced Resectable Cutaneous Squamous Cell Cancer of the Head and Neck with PD-1 Blockade
- Open Access
- 1 September 2026
- Published by American Association for Cancer Research (AACR)
Supplemental Figure 2 from Nonoperative Management of Locally Advanced Resectable Cutaneous Squamous Cell Cancer of the Head and Neck with PD-1 Blockade
Supplemental Figure 2 from Nonoperative Management of Locally Advanced Resectable Cutaneous Squamous Cell Cancer of the Head and Neck with PD-1 Blockade
- 1 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure 2 from Nonoperative Management of Locally Advanced Resectable Cutaneous Squamous Cell Cancer of the Head and Neck with PD-1 Blockade
Supplemental Figure 2 from Nonoperative Management of Locally Advanced Resectable Cutaneous Squamous Cell Cancer of the Head and Neck with PD-1 Blockade
- Open Access
- 1 September 2026
- Published by American Association for Cancer Research (AACR)
Supplemental Figure 4 from Nonoperative Management of Locally Advanced Resectable Cutaneous Squamous Cell Cancer of the Head and Neck with PD-1 Blockade
Supplemental Figure 4 from Nonoperative Management of Locally Advanced Resectable Cutaneous Squamous Cell Cancer of the Head and Neck with PD-1 Blockade
- 1 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure 4 from Nonoperative Management of Locally Advanced Resectable Cutaneous Squamous Cell Cancer of the Head and Neck with PD-1 Blockade
Supplemental Figure 4 from Nonoperative Management of Locally Advanced Resectable Cutaneous Squamous Cell Cancer of the Head and Neck with PD-1 Blockade
- Open Access
- 1 September 2026
- Published by American Association for Cancer Research (AACR)
Supplemental Figure 6 from Nonoperative Management of Locally Advanced Resectable Cutaneous Squamous Cell Cancer of the Head and Neck with PD-1 Blockade
Supplemental Figure 6 from Nonoperative Management of Locally Advanced Resectable Cutaneous Squamous Cell Cancer of the Head and Neck with PD-1 Blockade
- 1 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure 6 from Nonoperative Management of Locally Advanced Resectable Cutaneous Squamous Cell Cancer of the Head and Neck with PD-1 Blockade
Supplemental Figure 6 from Nonoperative Management of Locally Advanced Resectable Cutaneous Squamous Cell Cancer of the Head and Neck with PD-1 Blockade
- Open Access
- 1 September 2026
- Published by American Association for Cancer Research (AACR)
Supplemental Figure 8 from Nonoperative Management of Locally Advanced Resectable Cutaneous Squamous Cell Cancer of the Head and Neck with PD-1 Blockade
3-Month Landmark Analysis Overall Survival, 3-month Landmark Analysis Disease-Specific Survival, 3-month Landmark Analysis Progression-Free Probability.
- 1 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure 8 from Nonoperative Management of Locally Advanced Resectable Cutaneous Squamous Cell Cancer of the Head and Neck with PD-1 Blockade
3-Month Landmark Analysis Overall Survival, 3-month Landmark Analysis Disease-Specific Survival, 3-month Landmark Analysis Progression-Free Probability.
- Open Access
- 1 September 2026
- Published by American Association for Cancer Research (AACR)
Supplemental Figure 5 from Nonoperative Management of Locally Advanced Resectable Cutaneous Squamous Cell Cancer of the Head and Neck with PD-1 Blockade
Supplemental Figure 5 from Nonoperative Management of Locally Advanced Resectable Cutaneous Squamous Cell Cancer of the Head and Neck with PD-1 Blockade
- 1 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure 5 from Nonoperative Management of Locally Advanced Resectable Cutaneous Squamous Cell Cancer of the Head and Neck with PD-1 Blockade
Supplemental Figure 5 from Nonoperative Management of Locally Advanced Resectable Cutaneous Squamous Cell Cancer of the Head and Neck with PD-1 Blockade
- Open Access
- 1 September 2026
- Published by American Association for Cancer Research (AACR)
Supplemental Figure 7 from Nonoperative Management of Locally Advanced Resectable Cutaneous Squamous Cell Cancer of the Head and Neck with PD-1 Blockade
Supplemental Figure 7 from Nonoperative Management of Locally Advanced Resectable Cutaneous Squamous Cell Cancer of the Head and Neck with PD-1 Blockade
- 1 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure 7 from Nonoperative Management of Locally Advanced Resectable Cutaneous Squamous Cell Cancer of the Head and Neck with PD-1 Blockade
Supplemental Figure 7 from Nonoperative Management of Locally Advanced Resectable Cutaneous Squamous Cell Cancer of the Head and Neck with PD-1 Blockade
- Open Access
- 1 September 2026
- Published by American Association for Cancer Research (AACR)
Supplemental Table 1 from Nonoperative Management of Locally Advanced Resectable Cutaneous Squamous Cell Cancer of the Head and Neck with PD-1 Blockade
Supplemental Table 1 from Nonoperative Management of Locally Advanced Resectable Cutaneous Squamous Cell Cancer of the Head and Neck with PD-1 Blockade
- 1 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Table 1 from Nonoperative Management of Locally Advanced Resectable Cutaneous Squamous Cell Cancer of the Head and Neck with PD-1 Blockade
Supplemental Table 1 from Nonoperative Management of Locally Advanced Resectable Cutaneous Squamous Cell Cancer of the Head and Neck with PD-1 Blockade